Meeting
2011 ASCO Annual Meeting
Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
Authors
T. Mok
Prince of Wales Hospital, Shatin, Hong Kong
T. Mok , E. Tan , K. Park , J. Jac , M. Han , F. C. Payumo , M. Credi , K. McKee , M. M. Cotreau , P. Bhargava , W. Slichenmyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Metastatic
Clinical Trial Registration Number
NCT01039948
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS213)
Abstract #
TPS213
Poster Bd #
50C
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase 1b study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
First Author: E. Tan
Poster
2014 ASCO Annual Meeting
Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).
First Author: Bartomeu Massuti
Poster
2014 ASCO Annual Meeting
Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy.
First Author: Tomonori Hirashima
Poster
2023 ASCO Annual Meeting
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.
First Author: Yusuke Okuma